Quick Answer
BioNexus Gene Lab Corp reported Cash And Cash Equivalents At Carrying Value of $2.12 million for the year ending 2021.
- BioNexus Gene Lab Corp showed a decrease of -23.8% in Cash And Cash Equivalents At Carrying Value from 2020 to 2021.
- This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 6, 2022.
- XBRL data for this metric is available from 2018 to 2021 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $839.1 thousand | Q3 2018: $1.42 million | Q2 2019: $1.14 million | Q3 2019: $977.1 thousand | Q1 2020: $1.40 million | Q2 2020: $1.29 million | Q3 2020: $2.19 million | Q4 2020: $2.79 million | Q1 2021: $2.47 million | Q2 2021: $1.48 million | Q3 2021: $1.70 million | Q4 2021: $2.12 million | Q1 2022: $1.84 million.
- Over the full 4 years of available data (2018 to 2021), BioNexus Gene Lab Corp's Cash And Cash Equivalents At Carrying Value has grown by 68.5%.
- Historical annual values: Fiscal year 2021: $2.12 million | Fiscal year 2020: $2.79 million | Fiscal year 2019: $859.1 thousand | Fiscal year 2018: $1.26 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: